Siri in iOS 27 beta 3 works with third-party apps, seamlessly pulling relevant context and information from them. This is a significant upgrade that would make the Siri AI experience much better. Siri ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. July 3 update: this post, first published on June 30, has been updated with more details of ...

Apple’s iOS 26.6 Beta 3, released earlier this week, marks a significant milestone in the beta testing process, with a clear emphasis on improving stability and performance. Phones & Drones highlights ...

One excels at fitness, the other at sleep. After extensive testing, here's what you need to know about these smart health tracking devices.

Aaron Johnson, who was appointed the CEO of the company last month, outlined what he calls a five-point recovery plan. Watch below: Past coverage on Priority Waste pickup problems Priority Waste ...

The City and County of Honolulu’s Department of Planning and Permitting announced Tuesday that it is launching Priority Review, a program that encourages applicants to use its AI-guided software, ...

Two years. Count 'em, it's been two years since Apple Intelligence was unveiled in 2024 for iOS 18. The showstopper feature Apple presented at the time was a much-needed Siri upgrade boasting chatbot ...

Google has initiated beta testing for Gmail Live on Android and iOS, delivering on a major promise from Google I/O. The new feature allows premium Google AI Pro and Ultra subscribers to ...

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and ...

Please provide your email address to receive an email when new articles are posted on . If approved, Enspryng would be the first at-home subcutaneous treatment for thyroid eye disease. The FDA’s ...

Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...